Case Report
Volume: 6 | Issue: 1 | Published: Jan 13, 2022 | Pages: 1 - 4 | DOI: 10.24911/ejmcr/173-1620567671
COVID-19 infection in a patient with Behcet's Disease
Authors: George Johnson , Alice Martha Schofield , John Kirwan , Robert Moots
Article Info
Authors
George Johnson
Histopathology Trainee, North Bristol NHS Trust, Bristol, UK
Alice Martha Schofield
Registrar in Gynecological Oncology, Liverpool Women’s Hospital, Liverpool, UK
John Kirwan
. Consultant in Gynecological Oncology, Liverpool Women’s Hospital, Liverpool, UK
Robert Moots
Consultant Rheumatologist, Behçet’s Centre of Excellence, Aintree University Hospital Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
Publication History
Received: May 14, 2021
Revised: November 29, 2021
Accepted: November 29, 2021
Published: January 13, 2022
Abstract
Background: We are continually learning how to best manage patients testing positive for SARS-CoV-2 [coronavirus disease 2019 (COVID-19)]. This is particularly challenging in rare autoimmune conditions, where immune system dysfunction, whether by disease or treatment, has the potential to impact on the course of COVID-19 in several ways. Case Presentation: We present the case of a 52-year-old female with Behcets Disease, treated by immunosuppressive drugs, who tested positive for COVID-19 during the first month of the pandemic in the United Kingdom. In this case a multidisciplinary team approach, involving gynecological, rheumatological, microbiological, and respiratory teams was essential in ensuring the best outcome for the patient. Conclusion: Our patient had a favorable outcome; she did not require intensive care admission and has recovered. This case supports the hypothesis that the chronic immunosuppression may confer a degree of protection against severe COVID-19 disease, potentially by mitigating the pro- inflammatory cytokine responsible for the respiratory failure seen in severe cases of the disease.
Keywords: Case report, Behcet's Disease, COVID-19, immunosuppression, autoimmune disease, multidisciplinary team, green
Pubmed Style
George Johnson, Alice Martha Schofield, John Kirwan, Robert Moots. COVID-19 infection in a patient with Behcet's Disease. EJMCR. 2022; 13 (January 2022): 1-4. doi:10.24911/ejmcr/173-1620567671
Web Style
George Johnson, Alice Martha Schofield, John Kirwan, Robert Moots. COVID-19 infection in a patient with Behcet's Disease. https://ejmcr.com/articles/1079 [Access: December 25, 2024]. doi:10.24911/ejmcr/173-1620567671
AMA (American Medical Association) Style
George Johnson, Alice Martha Schofield, John Kirwan, Robert Moots. COVID-19 infection in a patient with Behcet's Disease. EJMCR. 2022; 13 (January 2022): 1-4. doi:10.24911/ejmcr/173-1620567671
Vancouver/ICMJE Style
George Johnson, Alice Martha Schofield, John Kirwan, Robert Moots. COVID-19 infection in a patient with Behcet's Disease. EJMCR. (2022), [cited December 25, 2024]; 13 (January 2022): 1-4. doi:10.24911/ejmcr/173-1620567671
Harvard Style
George Johnson, Alice Martha Schofield, John Kirwan, Robert Moots (2022) COVID-19 infection in a patient with Behcet's Disease. EJMCR, 13 (January 2022): 1-4. doi:10.24911/ejmcr/173-1620567671
Chicago Style
George Johnson, Alice Martha Schofield, John Kirwan, Robert Moots. "COVID-19 infection in a patient with Behcet's Disease." 13 (2022), 1-4. doi:10.24911/ejmcr/173-1620567671
MLA (The Modern Language Association) Style
George Johnson, Alice Martha Schofield, John Kirwan, Robert Moots. "COVID-19 infection in a patient with Behcet's Disease." 13.January 2022 (2022), 1-4. Print. doi:10.24911/ejmcr/173-1620567671
APA (American Psychological Association) Style
George Johnson, Alice Martha Schofield, John Kirwan, Robert Moots (2022) COVID-19 infection in a patient with Behcet's Disease. , 13 (January 2022), 1-4. doi:10.24911/ejmcr/173-1620567671